EnChannel Medical is developing a holistic cardiac electrophysiology platform that unifies magnetic-impedance navigation, intracardiac echocardiography, full-chamber 5D action-potential mapping, and mid-voltage pulsed-field ablation. The company’s lead systems include the DePolar® Mapping System and NanoAblate® PFA System, which are currently investigational. Proceeds from the recent financing will accelerate product development and advance clinical registration trials in China and internationally. Management cites encouraging early clinical data presented at the Heart Rhythm Society meeting in April 2025. Financially, EnChannel completed an oversubscribed Series B of $82.2M (600M RMB) and previously raised $27.8M in a Series A in August 2023. Founded in 2020 by electrophysiology innovators from the U.S. and China, the company is headquartered in Guangzhou with an R&D subsidiary in Irvine, California.

Total raised

$84M

Funding rounds

1

Latest round

Series B

Latest activity

May 2025